公司資料
Aquestive Therapeutics 股價、新聞與催化劑
- 股票代碼:
- AQST
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
4.29 USD (+0.94%)
收盤價
最後更新: 2026年8月17日
493M USD
市值
股價為何變動
As of Aug 17, 2026, AQST closed up 0.94% at $4.29. No new same-company headline was identified in the current news window.
公司概覽
Oral Film Drug Delivery Company
Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions.
Anaphylm
Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without water or swallowing.
PharmFilm Platform
Aquestive's film technology controls drug loading, disintegration, and absorption in a compact dosage form and can be adapted across central nervous system and allergy products.
Non-Injectable Epinephrine Strategy
Anaphylm is intended to offer portable and intuitive epinephrine administration without an autoinjector while producing clinically relevant systemic exposure.
Global Regulatory Opportunity
Aquestive plans to use the Anaphylm clinical package for regulatory applications outside the United States, extending the program into Canada, Europe, the United Kingdom, and other markets.
未來催化劑
- Resubmission of the Anaphylm NDA in the third quarter of 2026.
- Submission of an Anaphylm regulatory application in Canada by the end of 2026.
- Submission of an Anaphylm regulatory application in the European Union in the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。